Evidence map›Paper›PMID 28235814›Full record

ArticleNeurology2017

Differentiating cognitive impairment due to corticobasal degeneration and Alzheimer disease.

Gregory S Day, Tae Sung Lim, Jason Hassenstab, Alison M Goate, Elizabeth A Grant, Catherine M Roe, Nigel J Cairns, John C Morris

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 41 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Cognitive impairment in Parkinson's disease and other parkinsonian syndromes.Journal of neural transmission (Vienna, Austria : 1996) · 2025
    Review
  9. Pathomechanisms of cognitive and behavioral impairment in corticobasal degeneration.Journal of neural transmission (Vienna, Austria : 1996) · 2023
    Review
  10. Article
  11. Article
  12. Article
  13. Neuropathology and emerging biomarkers in corticobasal syndrome.Journal of neurology, neurosurgery, and psychiatry · 2022
    Review
  14. Clinical Spectrum of Tauopathies.Frontiers in neurology · 2022
    Review
  15. Article
  16. Frontiers in aging neuroscience · 2021
    Article
  17. Article
  18. Article
  19. Tauopathies: Deciphering Disease Mechanisms to Develop Effective Therapies.International journal of molecular sciences · 2020
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Gregory S DayFrom the Charles F. and Joanne Knight Alzheimer Disease Research Center (G.S.D., T.S.L., J.H., A.M.G., E.A.G., C.M.R., N.J.C., J.C.M.), Department of Neurology (G.S.D., T.S.L., J.H., C.M.R., N.J.C., J.C.C.), Division of Biostatistics (E.A.G.), and Department of Pathology and Immunology (N.J.C.), Washington University School of Medicine (G.S.D., T.S.L., J.H., A.M.G., E.A.G., C.M.R., N.J.C., J.C.M.), St. Louis, MO; Ajou University School of Medicine (T.S.L.), Suwon, Republic of Korea; and Icahn School of Medicine at Mount Sinai (A.M.G.), New York, NY.
Tae Sung LimFrom the Charles F. and Joanne Knight Alzheimer Disease Research Center (G.S.D., T.S.L., J.H., A.M.G., E.A.G., C.M.R., N.J.C., J.C.M.), Department of Neurology (G.S.D., T.S.L., J.H., C.M.R., N.J.C., J.C.C.), Division of Biostatistics (E.A.G.), and Department of Pathology and Immunology (N.J.C.), Washington University School of Medicine (G.S.D., T.S.L., J.H., A.M.G., E.A.G., C.M.R., N.J.C., J.C.M.), St. Louis, MO; Ajou University School of Medicine (T.S.L.), Suwon, Republic of Korea; and Icahn School of Medicine at Mount Sinai (A.M.G.), New York, NY.
Jason HassenstabFrom the Charles F. and Joanne Knight Alzheimer Disease Research Center (G.S.D., T.S.L., J.H., A.M.G., E.A.G., C.M.R., N.J.C., J.C.M.), Department of Neurology (G.S.D., T.S.L., J.H., C.M.R., N.J.C., J.C.C.), Division of Biostatistics (E.A.G.), and Department of Pathology and Immunology (N.J.C.), Washington University School of Medicine (G.S.D., T.S.L., J.H., A.M.G., E.A.G., C.M.R., N.J.C., J.C.M.), St. Louis, MO; Ajou University School of Medicine (T.S.L.), Suwon, Republic of Korea; and Icahn School of Medicine at Mount Sinai (A.M.G.), New York, NY.
Alison M GoateFrom the Charles F. and Joanne Knight Alzheimer Disease Research Center (G.S.D., T.S.L., J.H., A.M.G., E.A.G., C.M.R., N.J.C., J.C.M.), Department of Neurology (G.S.D., T.S.L., J.H., C.M.R., N.J.C., J.C.C.), Division of Biostatistics (E.A.G.), and Department of Pathology and Immunology (N.J.C.), Washington University School of Medicine (G.S.D., T.S.L., J.H., A.M.G., E.A.G., C.M.R., N.J.C., J.C.M.), St. Louis, MO; Ajou University School of Medicine (T.S.L.), Suwon, Republic of Korea; and Icahn School of Medicine at Mount Sinai (A.M.G.), New York, NY.
Elizabeth A GrantFrom the Charles F. and Joanne Knight Alzheimer Disease Research Center (G.S.D., T.S.L., J.H., A.M.G., E.A.G., C.M.R., N.J.C., J.C.M.), Department of Neurology (G.S.D., T.S.L., J.H., C.M.R., N.J.C., J.C.C.), Division of Biostatistics (E.A.G.), and Department of Pathology and Immunology (N.J.C.), Washington University School of Medicine (G.S.D., T.S.L., J.H., A.M.G., E.A.G., C.M.R., N.J.C., J.C.M.), St. Louis, MO; Ajou University School of Medicine (T.S.L.), Suwon, Republic of Korea; and Icahn School of Medicine at Mount Sinai (A.M.G.), New York, NY.
Catherine M RoeFrom the Charles F. and Joanne Knight Alzheimer Disease Research Center (G.S.D., T.S.L., J.H., A.M.G., E.A.G., C.M.R., N.J.C., J.C.M.), Department of Neurology (G.S.D., T.S.L., J.H., C.M.R., N.J.C., J.C.C.), Division of Biostatistics (E.A.G.), and Department of Pathology and Immunology (N.J.C.), Washington University School of Medicine (G.S.D., T.S.L., J.H., A.M.G., E.A.G., C.M.R., N.J.C., J.C.M.), St. Louis, MO; Ajou University School of Medicine (T.S.L.), Suwon, Republic of Korea; and Icahn School of Medicine at Mount Sinai (A.M.G.), New York, NY.
Nigel J CairnsFrom the Charles F. and Joanne Knight Alzheimer Disease Research Center (G.S.D., T.S.L., J.H., A.M.G., E.A.G., C.M.R., N.J.C., J.C.M.), Department of Neurology (G.S.D., T.S.L., J.H., C.M.R., N.J.C., J.C.C.), Division of Biostatistics (E.A.G.), and Department of Pathology and Immunology (N.J.C.), Washington University School of Medicine (G.S.D., T.S.L., J.H., A.M.G., E.A.G., C.M.R., N.J.C., J.C.M.), St. Louis, MO; Ajou University School of Medicine (T.S.L.), Suwon, Republic of Korea; and Icahn School of Medicine at Mount Sinai (A.M.G.), New York, NY.
John C MorrisFrom the Charles F. and Joanne Knight Alzheimer Disease Research Center (G.S.D., T.S.L., J.H., A.M.G., E.A.G., C.M.R., N.J.C., J.C.M.), Department of Neurology (G.S.D., T.S.L., J.H., C.M.R., N.J.C., J.C.C.), Division of Biostatistics (E.A.G.), and Department of Pathology and Immunology (N.J.C.), Washington University School of Medicine (G.S.D., T.S.L., J.H., A.M.G., E.A.G., C.M.R., N.J.C., J.C.M.), St. Louis, MO; Ajou University School of Medicine (T.S.L.), Suwon, Republic of Korea; and Icahn School of Medicine at Mount Sinai (A.M.G.), New York, NY. jcmorris@wustl.edu.
Ajou University · KR

Funding

Smartphone-Based "Burst" Cognitive AssessmentsP01AG003991 · NIA · WASHINGTON UNIVERSITY · PI JOHN MORRIS · 1985 to 2026
$69.5M
WASHINGTON UNIVERSITY ALZHEIMERS DISEASE RESEARCH CENTERP50AG005681 · NIA · WASHINGTON UNIVERSITY · PI MORRIS, JOHN · 1985 to 2019
$52.1M
The natural history of AB accumulation in preclinical ADP01AG026276 · NIA · WASHINGTON UNIVERSITY · PI SCHINDLER, SUZANNE ELIZABETH · 2005 to 2025
$49.5M
Imaging CoreU01AG032438 · NIA · WASHINGTON UNIVERSITY · PI BATEMAN, RANDALL J · 2008 to 2009
$6.1M
NEURAL RESPONSE TO INSULIN RESISTANCE TREATMENTSK23DK094982 · NIDDK · WASHINGTON UNIVERSITY · PI HASSENSTAB, JASON J · 2012 to 2016
$814k
NIA NIH HHS P01 AG003991NIA NIH HHS P01 AG026276NIA NIH HHS P50 AG005681NIA NIH HHS U01 AG032438NIDDK NIH HHS K23 DK094982
6 · The paper itself

Abstract

objectiveTo identify clinical features that reliably differentiate individuals with cognitive impairment due to corticobasal degeneration (CBD) and Alzheimer disease (AD).

methodsClinical features were compared between individuals with autopsy-proven CBD (n = 17) and AD (n = 16). All individuals presented with prominent cognitive complaints and were evaluated annually with semistructured interviews, detailed neurologic examinations, and neuropsychological testing.

resultsSubstantial overlap was observed between individuals with dementia due to CBD and AD concerning presenting complaints, median (range) duration of symptoms before assessment (CBD = 3.0 [0-5.0] years, AD = 2.5 [0-8.0] years;

conclusionsCBD may mimic AD dementia early in its disease course. Interval screening for discriminating clinical features may improve antemortem diagnosis in individuals with CBD and prominent cognitive symptoms.

Indexed as

AgedAged, 80 and overAlzheimer DiseaseBasal GangliaCerebral CortexCognitive DysfunctionFemaleHumansLongitudinal StudiesMaleMiddle AgedNeurodegenerative DiseasesNeurologic ExaminationNeuropsychological TestsStatistics, Nonparametric

Identifiers

PMID28235814
PMCPMC5373780
OpenAlexW2590131349

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.